RNA gene-silencing cardiovascular program advances

AI SummaryClose X

Thalia Therapeutics plc has completed the initial chemistry synthesis for its cardiovascular RNA gene-silencing medicine, THAT-002, a dual-acting siRNA targeting PCSK9 and lipoprotein(a). Preclinical work, including in vitro studies, has commenced with WuXi AppTec, with in vivo studies scheduled for the fourth quarter, all on time and on budget. This advancement is a crucial step towards IND-enabling studies and potential FDA filing for human clinical trials, aiming to reduce global cardiovascular risk.

Disclaimer*

UK 100

Latest directors dealings